Kohlberg Kravis Roberts & Co (KKR), the US based global private equity firm, via its KKR Health Care Strategic Growth Fund II, has acquired Immedica Pharma AB, the Sweden based pharmaceutical company focused on the commercialization of medicines for rare diseases and specialty care products. Existing owner, Impilo AB, the Sweden based investment company, will reinvest to become an equal owner alongside KKR.
- Target – Immedica Pharma AB
- Buyer – Kohlberg Kravis Roberts & Co (kkr)
- Buyer – Impilo AB
- Seller – Impilo AB
